Please login to the form below

Not currently logged in
Email:
Password:

DTC spending triples in US

A US study has revealed that drug companies now spend 2.6 times 1996 levels on direct-to-consumer (DTC) advertising for drugs in the US.

A US study has revealed that drug companies now spend 2.6 times 1996 levels on direct-to-consumer (DTC) advertising for drugs in the US.

Researchers at the University of Pittsburgh Graduate School of Public Health found that total spending on pharmaceutical promotion increased to USD 29.9bn in 2005 from USD 11.4bn in 1996, or an annual growth rate of 10.6 per cent.

DTC advertising, which began back in 1996, has increased by 330 per cent over the past ten years.

The Pittsburgh team examined industry data from three market-research firms which track advertising spending by the pharmaceutical industry.

Study leader, Julie Donohue said: "Our analysis found that the trend toward increasing spending on direct-to-consumer advertising is likely to continue and efforts to enforce more stringent guidelines on such practices would require not only significant changes by the pharmaceutical industry but by the FDA as well."

2nd September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics